Cooperative Agreement U01CA294527
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Cooperative Agreement
Place of Performance
Nashville, TN 37203, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,035,138 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to Oregon Health & Science University (OHSU) to create a comprehensive 3D atlas mapping the molecular and cellular progression of pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals with germline BRCA1, BRCA2, or PALB2 gene variants. The 5-year project aims to better understand the diverse pathways by which low-grade...
The National Cancer Institute (NCI) awarded a five-year, $1,128,990 Cooperative Agreement to the Dana-Farber Cancer Institute (DFCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to construct the Myeloma Multidimensional Pre-Cancer Atlas (MMPCA). The goal of this project is to map the spatial interactions between early B cell clonal expansions and the microenvironment, chart the subclonal genomic structure at the single cell level across the spectrum of...
This $1,069,188 Cooperative Agreement award was made by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The funding supports a collaborative research project between the UCLA Neurosurgery team and the Caltech Spatial Single Cell team to construct a comparative spatial atlas of low-grade gliomas. The goal is to understand the molecular and cellular mechanisms at the low-grade stage that are predictive of malignant...
The U.S. National Cancer Institute (NCI) awarded a $1,069,873 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to The University of Texas MD Anderson Cancer Center to establish the Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D). This research center aims to develop a multimodal, single-cell, dynamic, and 3D spatial atlas of normal-appearing gastric mucosa, precancerous lesions, and advanced gastric...
The Cooperative Agreement awarded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) provides $1,019,013.00 to The Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The primary goals are to: Characterize the genetic and immunological events during the transition from pre-cancer to cancer in melanoma and cutaneous squamous cell carcinoma through a series of molecular assays,...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) provides $1,018,682 to Yale University to construct a spatiotemporal atlas of human follicular lymphoma (FL) transformation to diffuse large B-cell lymphoma (DLBCL) and angioimmunoblastic T-cell lymphoma (AITL) evolution. Through the application of high-plex immunofluorescence protein imaging and spatial whole transcriptome sequencing,...
This $1,004,570 Cooperative Agreement award from the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports the Ovarian Cancer Atlas Research Center (OCARC) at the University of Texas MD Anderson Cancer Center. The center will use advanced molecular and cellular profiling platforms to construct a three-dimensional (3D) atlas characterizing high-grade serous ovarian cancer (HGSOC) metastasis and the development of intrinsic...
This Cooperative Agreement award from the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will establish the Human Prostate Tumor Atlas Center (HPTAC) at Washington University in St. Louis. The $1,032,520 award, effective September 1, 2024, will support the development of a molecularly resolved spatial atlas of prostate cancer (PCa) that integrates multi-omics, imaging, and clinical data. The center will procure and characterize...
This federal Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.393 Cancer Cause and Prevention Research program, provides $399,187 to Virginia Commonwealth University (VCU) to investigate the role of ATG16L1 isoforms in colorectal cancer health disparities. The research aims to determine whether the ATG16L1 T300T isoform is a prognostic indicator of response and a predictive treatment biomarker for African American colorectal cancer patients. The project will use...
The National Cancer Institute (NCI) has awarded a 5-year, $720,252 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project, titled "Characterizing Genetic Risk of Cancer Across Diverse Populations Through Multi-Ancestry Epigenome Profiling and Chromatin QTL Discovery," aims to identify novel genetic variants associated with cancer risk in diverse ancestral...